NASDAQ · Health care

Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc. brought in $49.8M of revenue over the twelve months to September 30, 2026, up 7.4% from a year earlier. It posted a net loss of $72.2M. In fiscal 2025 capital spending exceeded operating cash flow by $165.8M. At September 30, 2026 it held $93.2M in cash against $56.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.

Watch EDIT in 60 seconds

Price

$2.51

-8.91% on the day · November 10, 2026

52-week range $1.66 to $3.94

Market cap

$384.7M

Revenue (last 12 months)

$49.8M

+7.4% year on year

Net margin

-145.0%

Key facts about Editas Medicine, Inc.

Net worth: Editas Medicine, Inc. has a market value (market cap) of $384.7M at the latest share price, and shareholders' equity of $84.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit: In fiscal 2025 revenue was $40.5M (+25.4% year on year), with a net loss of $160.1M. Over the 12 months to September 30, 2026: revenue $49.8M, net loss $72.2M.
Cash flow: In fiscal 2025 operations used $165.2M of cash.
Latest report: The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
Next earnings report: Editas Medicine, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

What Editas Medicine, Inc. does

Editas Medicine, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker EDIT.

Revenue and profit by year

Revenue

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	$40.5M	-$160M	-$160.1M	-$1.80	-$165.8M
2024	$32.3M	-$251.2M	-$237.1M	-$2.88	-$219.1M
2023	$78.1M	-$169.2M	-$153.2M	-$2.02	-$136.9M
2022	$19.7M	-$226M	-$220.4M	-$3.21	-$181.5M
2021	$25.5M	-$193.1M	-$192.5M	-$2.85	-$171.8M
2020	$90.7M	-$134.8M	-$116M	-$1.98	-$187M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Next report expected around March 8, 2027.

Estimated from its filing rhythm: 52 weeks after its report of March 9, 2026. Not a date the company has announced. See the report calendar · Earnings, quarter by quarter

Where EDIT ranks in Health care

Revenue$40.5M

#416 of 751 in Health care · Bottom 45%

Revenue growth+25.4%

#154 of 532 in Health care · Top 29%

Net margin-395.0%

#510 of 544 in Health care · Bottom 6%

Free cash flow margin-409.3%

#466 of 490 in Health care · Bottom 5%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Editas Medicine, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

November 9, 2026
Quarterly report 10-Q · period to September 30, 2026Revenue rose 37% to $10.4M versus the same quarter last year; diluted EPS -$0.15 versus -$0.28.
November 9, 2026
Quarterly results 8-K
October 27, 2026
Passive stake (5% or more) SCHEDULE 13G
October 8, 2026
Investor disclosure 8-K
September 9, 2026
Employee stock plan registration S-8
August 31, 2026
Shelf registration to sell securities S-3
August 14, 2026
Passive stake (5% or more) SCHEDULE 13G
August 5, 2026
Quarterly report 10-Q · period to June 30, 2026Revenue rose 232% to $11.9M versus the same quarter last year; diluted EPS -$0.15 versus -$0.63.
August 5, 2026
Quarterly results 8-K
July 29, 2026
Passive stake changed SCHEDULE 13G/A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 6, 2026. Insider transactions on SEC

Insider trades

What the people running Editas Medicine, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $19.1K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

Bought (open market)

last 90 days

Sold

$19.1K

last 90 days

Net sold

6,286

$19.1K

Date	Insider	What	Shares	Price	Value	Filing
November 5, 2026	O'Neill Gilmore NeilCEO, Director	Received as pay	43,567	-	-	Form 4
November 5, 2026	Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER	Received as pay	16,533	-	-	Form 4
September 3, 2026	O'Neill Gilmore NeilCEO, Director	Soldpre-planned (10b5-1)	5,124	$3.04	$15.6K	Form 4
September 3, 2026	Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER	Soldpre-planned (10b5-1)	709	$3.04	$2.2K	Form 4
September 3, 2026	Parison AmySVP, Chief Financial Officer	Soldpre-planned (10b5-1)	453	$3.04	$1.4K	Form 4
August 3, 2026	Parison AmySVP, Chief Financial Officer	Soldpre-planned (10b5-1)	678	$2.58	$1.7K	Form 4
July 28, 2026	Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER	Soldpre-planned (10b5-1)	4,928	$2.67	$13.2K	Form 4
June 3, 2026	Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER	Soldpre-planned (10b5-1)	731	$2.70	$2K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns EDIT

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Holder	Of class	Shares	Filed
Commodore Capital LP13G, passive with 3 related filers	9.9%	16,045,802	June 2, 2026
TCG Crossover GP III, LLC13G, passive with 2 related filers	9.9%	15,798,999	June 3, 2026
BlackRock, Inc.13G, passive	7.8%	11,937,882	October 27, 2026
ADAR1 Capital Management, LLC13G, passive with 1 related filers	5.8%	8,889,000	August 14, 2026
RA Capital Management, L.P.13G, passive with 3 related filers	5.8%	8,889,000	June 3, 2026

Latest filings below 5%: The Vanguard Group 0% (March 26, 2026); Deep Track Capital, LP 0% (February 14, 2025).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 215 managers reported a position.

Holder	Shares	Value	Change on quarter
TCG Crossover Management, LLC	11,111,111	$36M	new
BlackRock, Inc.	10,589,990	$34.3M	+1,326,678
RA Capital Management, L.P.	8,889,000	$28.8M	new
Commodore Capital LP	8,889,000	$28.8M	new
ADAR1 Capital Management, LLC	8,889,000	$28.8M	new
Vanguard Capital Management LLC	6,141,336	$19.9M	+1,936,967
Paradigm Biocapital Advisors LP	5,586,625	$18.1M	new
Opaleye Management Inc.	3,861,930	$12.5M	+1,934,933
Vanguard Portfolio Management LLC	3,598,339	$11.7M	+449,769
Woodline Partners LP	3,555,497	$11.5M	new
Vivo Capital, LLC	3,555,250	$11.5M	new
GordonMD Global Investments LP	3,127,000	$10.1M	new
Goldman Sachs Group Inc	2,614,036	$8.5M	+2,055,459
Geode Capital Management, LLC	2,569,072	$8.3M	+257,283
Renaissance Technologies LLC	2,468,919	$8M	-1,503,241
Logos Global Management LP	2,222,000	$7.2M	new
State Street Corp	2,191,803	$7.1M	+115,681
Marshall Wace, Llp	2,037,287	$6.6M	+1,826,979
D. E. Shaw & Co., Inc.	1,901,002	$6.2M	-42,891
Jpmorgan Chase & Co	1,862,494	$6M	-84,890

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

3 insiders reported holding 378,788 shares in total, about $948.9K at the last price.

Holder	Shares	As of
O'Neill Gilmore NeilCEO, Director	286,756	November 5, 2026
Burkly LindaEVP, CHIEF SCIENTIFIC OFFICER	78,193	November 5, 2026
Parison AmySVP, Chief Financial Officer	13,839	September 3, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about EDIT

What does Editas Medicine, Inc. do?

Editas Medicine, Inc. is a company in the Health care sector, listed on NASDAQ as EDIT. Its shares trade on NASDAQ under the ticker EDIT.

What is Editas Medicine, Inc.'s net worth?

Editas Medicine, Inc. has a market value (market cap) of $384.7M at the latest share price, and shareholders' equity of $84.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Editas Medicine, Inc. profitable?

No. Over the twelve months to September 30, 2026 it reported a net loss of $72.2M on revenue of $49.8M.

How much revenue does Editas Medicine, Inc. make?

Over the twelve months to September 30, 2026 Editas Medicine, Inc. reported revenue of $49.8M. That is 7.4% more than a year earlier.

When did Editas Medicine, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.

When is Editas Medicine, Inc.'s next earnings report?

Editas Medicine, Inc.'s next report is expected around March 8, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

PALI

Palisade Bio, Inc.

STRO

Sutro Biopharma, Inc.

LXEO

Lexeo Therapeutics, Inc.

FENC

Fennec Pharmaceuticals Inc.

CMPX

Compass Therapeutics, Inc.

IPSC

Century Therapeutics, Inc.

Compare EDIT with

Compare EDIT with any company

Follow EDIT

Get an email when Editas Medicine, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Where the numbers come from

Financial figures are the values Editas Medicine, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.